Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting

被引:220
作者
Cole, Adam J. [1 ]
David, Allan E. [1 ,3 ]
Wang, Jianxin [1 ,4 ]
Galban, Craig J. [2 ]
Hill, Hannah L. [1 ]
Yang, Victor C. [1 ,5 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Radiol, Ctr Mol Imaging, Sch Med, Ann Arbor, MI 48109 USA
[3] Ind Sci & Technol Network Inc, York, PA 17404 USA
[4] Fudan Univ, Dept Pharmaceut, Sch Pharm, Shanghai 201203, Peoples R China
[5] Tianjin Univ, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300072, Peoples R China
基金
美国国家卫生研究院;
关键词
Iron oxide nanoparticles; Magnetic nanoparticles; Magnetic targeting; Polyethylene glycol (PEG); Pharmacokinetics; Reticuloendothelial system (RES); SUPERPARAMAGNETIC NANOPARTICLES; DELIVERY; CHEMOTHERAPY; AGENTS; GENE;
D O I
10.1016/j.biomaterials.2010.11.040
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
While successful magnetic tumor targeting of iron oxide nanoparticles has been achieved in a number of models, the rapid blood clearance of magnetically suitable particles by the reticuloendothelial system (RES) limits their availability for targeting. This work aimed to develop a long-circulating magnetic iron oxide nanoparticle (MNP) platform capable of sustained tumor exposure via the circulation and, thus, potentially enhanced magnetic tumor targeting. Aminated, cross-linked starch (DN) and aminosilane (A) coated MNPs were successfully modified with 5 kDa (A5, D5) or 20 kDa (A20. D20) polyethylene glycol (PEG) chains using simple N-Hydroxysuccinimide (NHS) chemistry and characterized. Identical PEG-weight analogues between platforms (A5 & D5, A20 & D20) were similar in size (140-190 nm) and relative PEG labeling (1.5% of surface amines - A5/D5, 0.4% - A20/D20), with all PEG MNPs possessing magnetization properties suitable for magnetic targeting. Candidate PEG MNPs were studied in RES simulations in vitro to predict long-circulating character. D5 and D20 performed best showing sustained size stability in cell culture medium at 37 degrees C and 7 (D20) to 10 (D5) fold less uptake in RAW264.7 macrophages when compared to previously targeted, unmodified starch MNPs (D). Observations in vitro were validated in vivo, with D5 (7.29 h) and 020 (11.75 h) showing much longer half-lives than D (0.12 h). Improved plasma stability enhanced tumor MNP exposure 100 (D5) to 150 (D20) fold as measured by plasma AUC(0-infinity). Sustained tumor exposure over 24 h was visually confirmed in a 9L-glioma rat model (12 mg Fe/kg) using magnetic resonance imaging (MRI). Findings indicate that a polyethylene glycol modified, cross-linked starch-coated MNP is a promising platform for enhanced magnetic tumor targeting, warranting further study in tumor models. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2183 / 2193
页数:11
相关论文
共 40 条
[1]  
Alexiou C, 2007, ANTICANCER RES, V27, P2019
[2]   Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors [J].
Chertok, Beata ;
Moffat, Bradford A. ;
David, Allan E. ;
Yu, Faquan ;
Bergemann, Christian ;
Ross, Brian D. ;
Yang, Victor C. .
BIOMATERIALS, 2008, 29 (04) :487-496
[3]   Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration [J].
Chertok, Beata ;
David, Allan E. ;
Yang, Victor C. .
BIOMATERIALS, 2010, 31 (24) :6317-6324
[4]   Comparison of Electron Spin Resonance Spectroscopy and Inductively-Coupled Plasma Optical Emission Spectroscopy for Biodistribution Analysis of Iron-Oxide Nanoparticles [J].
Chertok, Beata ;
Cole, Adam J. ;
David, Allan E. ;
Yang, Victor C. .
MOLECULAR PHARMACEUTICS, 2010, 7 (02) :375-385
[5]   Magnetic nanoparticles for drug delivery [J].
Dobson, J .
DRUG DEVELOPMENT RESEARCH, 2006, 67 (01) :55-60
[6]   Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery [J].
Dobson, J .
GENE THERAPY, 2006, 13 (04) :283-287
[7]   CRITICAL EVALUATION OF PRINCIPLES GOVERNING ADVANTAGES OF INTRA-ARTERIAL INFUSIONS [J].
ECKMAN, WW ;
PATLAK, CS ;
FENSTERMACHER, JD .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (03) :257-285
[8]  
Ferrari M., 2006, BIOMEMS BIOMEDICAL N, P227
[9]   Poly(ethylene glycol) surface coated magnetic particles [J].
Flesch, C ;
Unterfinger, Y ;
Bourgeat-Lami, E ;
Duguet, E ;
Delaite, C ;
Dumas, P .
MACROMOLECULAR RAPID COMMUNICATIONS, 2005, 26 (18) :1494-1498
[10]   Magnetic nanoparticles for cancer therapy [J].
Goya, G. F. ;
Grazu, V. ;
Ibarra, M. R. .
CURRENT NANOSCIENCE, 2008, 4 (01) :1-16